Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Immunoprotein Diagnostics Market $26.9 Billion by 2031

The global market for immunoprotein diagnostics estimated to reach $26.9 billion by 2031, growing at a CAGR of 4.8% over the forecast period, driven by increasing incidence of infectious diseases and highly accurate, micro-level detection of immunoproteins in chronic disorders.

  • Other factors driving the market growth include rising demand for preventive healthcare measures, technological advances and a strong distribution network for immunoprotein diagnostic testing across the globe.
    • Prominent technologies driving the immunoprotein diagnostic market include radioimmunoassay, enzyme based immunoassay, chemiluminescence assay, immunofluorescence, immunoturbidity, and immunoprotein electrophoresis.
  • In response to the growing COVID-19 pandemic and shortages of laboratory-based molecular testing capacity and reagents, multiple diagnostic test manufacturers have developed and begun selling rapid and easy-to-use devices to facilitate testing outside of laboratory settings.
    • These simple test kits are based either on detection of proteins from the COVID-19 virus in respiratory samples (e.g. sputum, throat swab) or detection, in blood or serum, of human antibodies generated in response to infection.
Global Immunoprotein Diagnostics Market

The global market for immunoprotein diagnostics report provides market size ($million 2021 to 2031), market share, growth trends and forecast (CAGR%, 2024 to 2031). 

The global immunoprotein diagnostic testing market segmented by assay technology (chemiluminescence assay, enzyme-based immunoassay, immunofluorescence assay, immunoprotein electrophoresis, immunoturbidity assay or particle-enhanced turbidimetric immunoassay, radioimmunoassay), immunoprotein type (complement system proteins diagnostic tests, c-reactive protein diagnostic tests, free light chain diagnostic tests, haptoglobin diagnostic tests, immunoglobulin diagnostic tests, pre-albumin diagnostic tests), application (allergy testing, autoimmune disease testing, endocrine testing, infectious disease testing, oncology testing, toxicology testing), and geography.

  • Based on the assay technologies, the enzyme-linked immunosorbent assay (ELISA) segment accounted for the largest share of the total immunoprotein diagnostics market.
    • ELISA is the most widely used technique in the diagnosis of diseases such as human immunodeficiency virus (HIV) infection, hepatitis, tuberculosis, malaria, and various others.
      • ELISA has wider spectrum of applications in the diagnostics market due to its high accuracy, ease of use, and low cost.
        • ELISA can be used to quantify antigens as well as antibodies in a sample using modified ELISA techniques, namely, indirect ELISA, competitive ELISA, and sandwich ELISA.
          • The applications of ELIZA include the diagnosis of diseases such as HIV infection, tuberculosis, dengue, and Bordetella pertussis infections among others.
  • However, the chemiluminescence assays (CLIA) segment expected to expand at the fastest CAGR during the next few years, as these tests have been widely employed in disease diagnosis, allergy testing, autoimmune disease testing, growth deficiency identification, cancer screening, as well as drug abuse testing.
    • CLIA enables sensitive and high throughput screening of antigens coupled with low cost and simple procedure leading to accelerated adoption in the diagnostic centers and hospitals.
      • The wide range of applications of CLIA include diagnosing infection of H. pylori, Herpes Simplex Virus (HSV), cytomegalovirus and other bacterial and viral causative agents.
  • The radioimmunoassay (RIA), although highly sensitive and accurate, held the smallest share of the global market, due to the requirement of specialized equipment and radioactive substances.

The global market for immunoprotein detection testing research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.

  • Geographically, the North America region held the largest share of the global immunoprotein diagnostics market, followed by the Europe region, driven by demand for quicker diagnostic services for critical diseases such as viral infections and cancer.
    • Other major factors boosting market growth include rapidly growing elderly population, availability and demand for better and faster diagnostic services at hospitals and diagnostic laboratories, and increasing trend for preventive healthcare in the developed countries.
      • Rising incidences of cancer, allergies, and cases of drug abuse have been a major concern in the developed countries.
  • The immunoprotein diagnostic testing market has reached near saturation in North America and Europe, owing to shifting focus of leading companies towards more lucrative options in emerging economies such as China, India, Brazil and Mexico.
    • On the other hand, the Asia Pacific and Latin America regions holds growth potential in developing countries, due to increasing incidence of chronic and infectious diseases and rising demand for low cost diagnostic tests.
      • High prevalence of diseases such as HIV/AIDS, tuberculosis, dengue, malaria and many others with high mortality rates have fueled the need for rapid and accurate diagnosis in Asia Pacific and rest of the world regions.
        • In addition, preventive health checkup by corporate organizations, pre-policy checkup by insurance companies, and discounted packages given by hospitals are other factors supporting market growth in these markets.

The global immunoprotein testing market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major competitors operating in the global market for immunoprotein diagnostics and included in this report are Abbott Laboratories, Inc., Abcam plc, DiaSorin S.p.A., Enzo Life Sciences, Inc., Fujirebio Diagnostics, Inc., Omega Diagnostics Group plc, Randox Laboratories Ltd., Roche Holding AG, Siemens Healthineers AG, The Binding Site Group Ltd., and Thermo Fisher Scientific, Inc.

  • Assay Technology
    • Chemiluminescence Assay (CLIA)
    • Enzyme-based Immunoassay (ELISA)
    • Immunofluorescence Assay (IFA)
    • Immunoprotein Electrophoresis (IEP)
    • Immunoturbidity Assay [Particle-enhanced Turbidimetric Immunoassay (PETIA)]
    • Radioimmunoassay (RIA)
  • Immunoprotein Type
    • Complement System Proteins Diagnostic Tests
    • C-Reactive Protein (CRP) Diagnostic Tests
    • Free Light Chain Diagnostic Tests
    • Haptoglobin Diagnostic Tests
    • Immunoglobulin Diagnostic Tests
    • Pre-albumin Diagnostic Tests
  • Application
    • Allergy Testing
    • Autoimmune Disease Testing
    • Endocrine Testing
    • Infectious Disease Testing
    • Oncology Testing
    • Toxicology Testing
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Abbott Laboratories, Inc.
    • Abcam plc
    • DiaSorin S.p.A.
    • Enzo Life Sciences, Inc.
    • Fujirebio Diagnostics, Inc.
    • Omega Diagnostics Group plc
    • Randox Laboratories Ltd.
    • Roche Holding AG
    • Siemens Healthineers AG
    • The Binding Site Group Ltd.
    • Thermo Fisher Scientific, Inc.

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com